** Shares of Shanghai Junshi Biosciences Co Ltd surge 10.1% to HK$12.26, their highest since Aug. 23, on course for the second consecutive session of gain

** Stock on track for the biggest one-day pct rise since April 9; sixth biggest pct gainer in healthcare index , which rises 2.3%

** Company says European Commission has approved for marketing of toripalimab for treatment of metastatic nasopharyngeal carcinoma, or a malignant tumor in epithelium of the nasopharynx which is common types of head and neck cancers

** Says the approval is applicable to all 27 member states of the European Union, Iceland, Norway and Liechtenstein

** Shanghai-listed stock rises 4% to 25.39 yuan, highest since Sept. 13

** Hang Seng Commerce & Industry Index adds 1.4% and Hang Seng Index rises 1.6%

** Hong Kong stock dropped 42.7% YTD, Shanghai shares down 41.6% YTD

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))